Background. The objective of this study is to evaluate the response of the musculoskeletal system to enzyme replacement therapy in a group of patients with Mucopolysaccharidosis (MPS).
BACKGROUND
Mucopolysaccharidosis (MPS) are a group of genetic disease caused by a deficiency of lysosomal enzymes responsible for breaking down glycosaminoglycans (GAG) leading to accumulation the GAGs in the lysosomes [1] [2] [3] . These orthopedic disorders are clinically characterized by severe skeletal dysplasia along with systemic disease.
The accumulation of GAGs in the affected patient's cells results in a series of signs and symptoms, all parts of a clinical condition which compromises bones and joints, airways, the cardiovascular system and many other organs and tissues. Sometimes even cognitive function is compromised [4] .
GAGs are important for the function of connective tissues. Thus, MPS manifests itself as a severe connective tissue disorder, with skeletal abnormalities being the most debilitating aspect of this disorder. The accumulation of GAGs induces molecular abnormalities, poorly organized connective tissue matrices and an elevation of pro-inflammatory markers such as tumor necrosis factor alpha (TNFα) [5, 6] . These abnormalities lead to inflammation, apoptosis of hyaline cartilage and hyperplasia of synovial membranes. Therefore, the involvement of the musculoskeletal system or "dysostosis multiplex" is a common point in all cases of MPS. This involvement is characterized by osteoarticular deformities (kyphosis, scoliosis, knee valgus, equinus foot), joint stiffness with a loss of range of motion (ROM) and upper motor neuron impairment (myelopathy, hypertonia and spasticity) [6] .
A permanent cure for the enzymatic defect may be able to be reached through gene therapy, but there is still a long way to go [4] . Current treatment for MPS consists of enzyme replacement therapy (ERT), which has been approved for clinical use in MPS types I, II and VI [4] . The prevention and care of complications is also an important part of treatment, including support measures (which should be a part of regular multidisciplinary care for these patients) [4] .
The objective of this study is to evaluate the response of the musculoskeletal system to ERT in a group of 22 patients undergoing treatment at the Professor Edgard Santos University Hospital (HUPES).
MATERIAL AND METHODS
A retrospective study was done based on medical records from 22 patients with different types of MPS (I, II and VI) who were treated with ERT through the genetics service of HUPES. The study was done in accordance with the Ethical standards of the 1964 Declaration of Helsinki as revised in 2000; approved and authorized by the local Ethical Committee of the Institution; all of those responsible for the patients who participated gave the informed consent prior being included into the study.
The standard ERT treatments for MPS are as follows: for MPS I, one intravenous administration of 0.58 mg/kg of laronidase per week; for MPS II, one intravenous administration of 0.50 mg/kg of idursulfase is given weekly; for the treatment of MPS VI, an intravenous administration of 1 mg/kg of galsulfase per week. The marketing and use of these drugs in the treatment of patients with MPS in Brazil was approved by the National Health Surveillance Agency (ANVISA), and its dosing regimen was made accord ing to recommendations by the Brazilian Group of Experts [4] .
Patient data were evaluated by at least two of the authors and at two stages: at the start of ERT and after an average of 21.4 months. All patients were evaluated clinically by means of a standardized form for the examination of the musculoskeletal system, previously developed by the research team. This form contained general information (socio-demographic and clinical data) as well as specific data from the locomotor system examination.
Specific data collected on the form were: an assessment of global motor function; measured range of motion of the knee, elbow, and shoulder joints; evaluation of the main deep tendon reflexes (brachioradialis, triceps, biceps, patellar, and Achilles); and an evaluation of hand function. Global motor function was measured using a score from the GMFCS (Global Motor Function Classification System) [7] , which is an evaluation system that was initially created for patients with cerebral palsy. The joints' ranges of mo tion were measured using a simple universal goniometer [8] , and reflexes were evaluated in the conventional way, using the Wexler Scale [9] for their quantification. Hand function was graded using the scale proposed by Haddad et al. [10] .
For research purposes, data from the start of treatment were combined to form the "pre-treatment" group and data from after treatment were combined to form the "post-treatment" group. The data from the two groups were presented in descriptive tables and a comparison was done between them to evaluate the significant differences between the pre and post-treatment periods. Discrete variables were compared using Wilcoxon's test, and continuous variables were evaluated by the paired t-test. A 0.05 significance level was adopted for all tests.
RESULTS
Twenty-two patients with MPS between the ages of 7 months and 18 years and with a mean age of 9.7 years were evaluated. Of these patients, three (13.63%) had type I, eight (36.36%) had type II and eleven (50%) had type IV MPS.
After a period of 21.4 months of ERT, 3 patients classified under the Gross Motor Function Classifica tion System (GMFCS) as type 5 passed away and 1 patient was withdrawn from the study for having interrupted ERT, totaling 4 losses from the initial group (18.18%).
The GMFCS includes 5 levels of motor impairment, from the lightest impairment [1] to the most severe [5] . However, due to the small sample size, the patients were divided into two groups: those with GMFCS equal to 1 (the best possible level) and those classified higher than 1 according to the GMFCS (the group with significant motor impairment). The overall result of the ERT based on the GMFCS score can be found in Table 1 .
The ROM of the knees and elbows did not improve significantly, while the ROM of the shoulders saw a statistically significant improvement. The right shoulder developed from an average of 59.7º to 78.4º (p=0.017), and the left shoulder went from 65.2º to 80.2º (p=0,036), as shown in Table 2 . Table 3 shows joint ROM divided according to type of MPS.
The neuromotor analysis was based on evaluation of the brachioradialis, triceps, biceps, patellar, and Achilles deep tendon reflexes on both sides of the body. Hyperreflexia was considered to be the presence of three or more exacerbated reflexes (according to Wexler's scale), with or without clonus; Hand function was evaluated and the results obtained by Haddad scale was compared with GMFCS in search of any improvement after the therapy. Tables 4 and 5 show that there were no neuromotor alterations in both hyperreflexia and hand function after ERT. 
DISCUSSION
In the total group of patients, 13 (59.1%) maintained or improved their motor score and 8 (36.3%) ended up with a worse motor score. In the group with a GMFCS score equal to 1, motor function maintained a stable level in the majority of patients: the scores of 5 patients (37.5%) dropped 1 level and 1 patient (7.4%) dropped 2 levels; this group could not experience improved scores. In the GMFCS > 1 group, motor function improved in 3 patients (37.5%) and stayed stable in 2 (25%); in this group there was no improvement seen in patients classified as level 4 and all level 5 patients passed away (37.5%). It should be noted that despite these figures, there was no statistical significance in these findings.
These data indicate that ERT may be capable of stabilizing the motor function score of the majority of patients, and may even improve the score of patients classified as two or three. ERT did not have any effect on patients with a score of four, nor did it change fatal outcomes in patients with a motor function score of five. It is possible that ERT only exerts an effect on patients with a score less than four, but due to the small sample size of this study, other similar studies should confirm these preliminary findings.
Haskins et al. [11] argue that ERT should be started as early as possible, making an early diagnosis necessary through adequate neonatal screening tests. They also demonstrated, using animal models, that sy novial joints and the central nervous system are difficult to reach with enzyme therapy, and the pathogenesis of the lesions in these tissues, such as the defects in collagen biosynthesis and the development of inappropriate neurite synapses, is challenging. The refore, stopping the progression and natural course of MPS may already be considered a good treatment result.
Our results also showed a significant improvement in range of motion of shoulder flexion. This improvement was also seen in patients with MPS VI and II, although the finding was not statistically significant. The elbow and knee joints did not show increased ROM, however stability was achieved because there was no decrease in the mobility of these joints.
The findings of this study align with the results of multiple other studies which evaluate ERT in patients with MPS I [12] [13] [14] [15] . The study by Sifuentes et al. [12] showed an improvement in shoulder flexion and extension after one to two years of treatment. TylkiSzimanaska et al. [13] and Clarke et al. [14] , in longterm follow-up studies, also found that the only ROM improvement was in shoulder flexion. Kakkis et al. [15] was the only author who described simultaneous improvement of two joints: shoulder flexion and elbow extension. All these authors agree that the increase in shoulder ROM had a significant influence on improved upper limb function as well as the ability to perform activities of daily living, especially in self-care [12] [13] [14] [15] .
Wraith et al. [16] and Cox-Brinkman et al. [17] found no ROM improvement in patients with MPS type I undergoing ERT. In the first study the authors report the results of 26 months of treatment. They later report results after 3.5 to 4 years of treatment with the same group [16] and find significant differences in shoulder ROM, especially with respect to fle xion range. In the study by Cox-Brinkman et al. [17] , 6 patients were evaluated over the course of 12 months during ERT; the small sample size and short follow-up may have influenced the failure to detect an improved ROM in the evaluated joints.
The small sample size of this study sets a limitation for the extrapolation of the results. However, when dealing with a rare disease it is not possible to perform studies with a large sample. Certainly, gathering data from multiple studies with few patients will be a way to give consistency to individual clinical findings.
This study contributes significantly to the theme in question by being one of the rare works in the literature that evaluates the changes ERT has on the musculoskeletal system of patients with MPS VI and II. It is also the only study to our knowledge that uses Tab. 4. HADDAD classification before and after ERT Tab. 5. Motor reflexes before and after ERT a global score for motor system evaluation, the GMFCS, in conjunction with joint ROM. Based on the data from this study, it is possible to conclude that ERT was able to stabilize motor function in the majority of patients (58.1%) and also significantly increased the range of motion of shoulder joints in patients with MPS.
